Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation with soluble IFN-gamma receptor: preliminary study

L Ozmen1, M Fountoulakis, R Gentz

  • 1Hoffmann-La Roche Ltd., CH-4002 Basel, Switzerland.

International Review of Experimental Pathology
|January 1, 1993
PubMed
Summary

An interferon-gamma (IFN-gamma) antagonist shows therapeutic potential for autoimmune diseases. A soluble mouse IFN-gamma receptor protein modified acute and chronic graft-versus-host disease in vivo experiments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving biogas production from anaerobic co-digestion of sewage sludge with a thermal dried mixture of food waste, cheese whey and olive mill wastewater.

Waste management (New York, N.Y.)·2017
Same author

Boosting biogas production from sewage sludge by adding small amount of agro-industrial by-products and food waste residues.

Waste management (New York, N.Y.)·2017
Same author

Pilot-scale anaerobic co-digestion of sewage sludge with agro-industrial by-products for increased biogas production of existing digesters at wastewater treatment plants.

Waste management (New York, N.Y.)·2016
Same author

Long-term stable production of monocyte-colony inhibition factor (M-CIF) from CHO microcarrier perfusion cultures.

Cytotechnology·2012
Same author

Development of a versatile computer integrated control system for bioprocess controls.

Cytotechnology·2012
Same author

Cell growth and protein formation on various microcarriers.

Cytotechnology·2012

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Interferon-gamma (IFN-gamma) plays a key role in immune responses.
  • Therapeutic strategies targeting IFN-gamma are being explored for autoimmune and allogeneic conditions.
  • Understanding IFN-gamma receptor interactions is crucial for developing antagonists.

Purpose of the Study:

  • To investigate the therapeutic potential of an IFN-gamma antagonist.
  • To characterize a soluble mouse IFN-gamma receptor (IFN-gamma R) as a prototype antagonist.
  • To evaluate the in vivo efficacy of the soluble IFN-gamma R in alloreactions.

Main Methods:

  • Expression of the external domain of mouse IFN-gamma R in insect cells using recombinant baculovirus.
  • Characterization of the expressed soluble IFN-gamma R.

Related Experiment Videos

  • In vivo administration of the soluble IFN-gamma R in mouse models.
  • Pharmacokinetic studies to determine blood half-life.
  • Assessment of the antagonist's effect on acute and chronic graft-versus-host disease (GVHD).

    • Main Results:

    • A soluble mouse IFN-gamma R was successfully expressed and characterized.
    • The soluble IFN-gamma R exhibited low antigenicity in vivo.
    • Pharmacokinetic studies revealed a blood half-life of 1-3 hours.
    • The soluble IFN-gamma R demonstrated efficacy in modifying acute and chronic GVHD, including lupus-like disease.

    Conclusions:

    • A soluble IFN-gamma R can serve as a prototype antagonist with therapeutic potential.
    • IFN-gamma antagonism is a viable strategy for treating conditions like GVHD and lupus-like diseases.
    • Further development of IFN-gamma antagonists may offer new treatment options for immune-mediated disorders.